Decode Age raised $1.7 million (approximately ₹14.48 crore) in a pre-Series A funding round. The funding round was led by Krishna Prasad Chigurupati. He is the chairman and managing director of Granules India. This investment is a major milestone in the company as it tries to further establish itself in the ever-changing aging biology and longevity research.
The funds recently obtained are allocated to multiple important projects that will enhance the technological and scientific strength of the company. One of the main areas of this investment will involve the growth of the biomarker discovery programs in the Decode Age. With improved versions of these programs, the company believes it can discover new age-related signs of biological aging that can be used to conduct more precise health-related tests and customized treatments.
Besides biomarker research, the startup will also enhance its multi-omics and microbiome research pipeline. Multi-omics refers to the combination of different biological data sets to have a comprehensive picture of human health. Through the optimization of this pipeline, Decode Age aims to enhance its accuracy in the analysis and deliver more detailed information on the interaction of the gut microbiome with the aging process. The funds will also be used to modernize the scientific and analytical facilities of the company so that the remaining research facilities will be on the leading edge of international standards.
Decode Age was founded in 2021. Decode Age functions on the frontier of the aging of biology, biomarkers, and the science of the gut microbiome. The main goal of the establishment of the company was to convert the biological signals involving the aging process into accurate and practical data. Through advanced testing methodology and precision-led intervention, the startup will offer people and professionals the means to comprehend and affect the aging process in a much efficient way.
Decode Age is currently working on the development of evidence-based supplements and longevity solutions that can be specifically associated with different aging pathways. The company has come up with its own advanced in-house platform, which includes a genome-scale gut microbiome analysis and metagenomics. The platform is intended to cater to a wide range of users, such as clinicians, academic researchers, and those who are interested in obtaining data-driven information about their own health experience. When these high-level analytical tools are integrated, we are able to get a better idea of what contributes to healthy aging.
Decode Age is in the process of aggressively growing its own internal scientific and product units as part of its growth strategy. This growth will lead to the ambition of the company to extend its longevity research to the Indian market. The startup will also expand its operations by recruiting expertise and making its innovative solutions accessible to a varied audience across the world.
Decode Age has been working closely with top academia and international research projects. These include its efforts associated with the Indian Institute of Science (IISc) and other global longevity programs. Such partnerships are necessary to produce quality microbiome and aging data that meet international research standards. These partnerships have the effect of ensuring that the findings of the company are added to the general scientific models of longevity.
With the company still continuing to revamp its infrastructure and increase its research pipelines, it is dedicated to delivering evidence-based solutions to cognitive health, metabolism, and cellular energy. By emphasizing data-driven insights and cross-border cooperation, Decode Age will have a strong impact on the area of longevity science, eventually contributing to the fact that people will have longer and healthier lives.
The well-received pre-Series A funding round makes Decode Age a powerful competitor in the field of longevity science. Having seasoned investors such as Krishna Prasad Chigurupati, the company will be in a position to continue with its mission of turning the biological signals of aging into both measurable and usable. With the combination of intensive research and accurate interventions, Decode Age is establishing a new pattern of how individuals and clinicians are tackling the issue of aging.